Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Authors: Kozono, David, Hua, Xing, Wu, Michael C., Tolba, Khaled A., Waqar, Saiama N., Dragnev, Konstantin H., Cheng, Haiying, Hirsch, Fred R., Mack, Philip C., Gray, Jhanelle E., Kelly, Karen, Borghaei, Hossein, Herbst, Roy S., Gandara, David R., Redman, Mary W.

Source: In Journal of Thoracic Oncology December 2024 19(12):1618-1629

Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay

Authors: Liu, Matthew, Vathiotis, Ioannis, Robbins, Charles J., Chan, Nay Nwe Nyein, Moutafi, Myrto, Burela, Sneha, Xirou, Vasiliki, Schalper, Kurt A., Herbst, Roy S., Syrigos, Konstantinos, Rimm, David L.

Source: In Modern Pathology September 2024 37(9)

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients

Authors: Brahmer, Julie R., Long, Georgina V., Hamid, Omid, Garon, Edward B., Herbst, Roy S., Andre, Thierry, Armand, Philippe, Bajorin, Dean, Bellmunt, Joaquim, Burtness, Barbara, Choueiri, Toni K., Cohen, Ezra E.W., Diaz, Luis A., Jr, Shitara, Kohei, Kulkarni, Girish, McDermott, David, Shah, Manish, Tabernero, Josep, Vogel, Arndt, Zinzani, Pier Luigi, Jafari, Niusha, Bird, Steven, Snyder, Ellen, Gause, Christine, Bracco, Oswaldo L., Pietanza, M. Catherine, Gruber, Todd, Ribas, Antoni

Source: In European Journal of Cancer March 2024 199

Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review

Authors: Majem, Margarita, Basch, Ethan, Cella, David, Garon, Edward B., Herbst, Roy S., Leighl, Natasha B.

Source: In Lung Cancer January 2024 187

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Authors: Herbst, Roy S., Wu, Yi-Long, John, Thomas, Grohe, Christian, Majem, Margarita, Wang, Jie, Kato, Terufumi, Goldman, Jonathan W., Laktionov, Konstantin, Kim, Sang-We, Yu, Chong-Jen, Vu, Huu Vinh, Lu, Shun, Lee, Kye Young, Mukhametshina, Guzel, Akewanlop, Charuwan, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A., Urban, Damien, Huang, Xiangning, Bolanos, Ana, Stachowiak, Marta, Tsuboi, Masahiro

Source: Journal of clinical oncology. 41(10):1830-1840

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100189911228.0x000001&indx=1&recIds=ETOCvdc_100189911228.0x000001

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

Authors: John, Thomas, Grohé, Christian, Goldman, Jonathan W., Shepherd, Frances A., de Marinis, Filippo, Kato, Terufumi, Wang, Qun, Su, Wu-Chou, Choi, Jin Hyuk, Sriuranpong, Virote, Melotti, Barbara, Fidler, Mary J., Chen, Jun, Albayaty, Muna, Stachowiak, Marta, Taggart, Sarah, Wu, Yi-Long, Tsuboi, Masahiro, Herbst, Roy S., Majem, Margarita

Source: In Journal of Thoracic Oncology September 2023 18(9):1209-1221

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer

Authors: Shafi, Saba, Aung, Thazin Nwe, Xirou, Vasiliki, Gavrielatou, Niki, Vathiotis, Ioannis A., Fernandez, Aileen, Moutafi, Myrto, Yaghoobi, Vesal, Herbst, Roy S., Liu, Linda N., Langermann, Sol, Rimm, David L.

Source: In Laboratory Investigation October 2022 102(10):1143-1149

Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology

Authors: Herbst, Roy S., Hatsukami, Dorothy, Acton, Dana, Giuliani, Meredith, Moushey, Allyn, Phillips, Jonathan, Sherwood, Shimere, Toll, Benjamin A., Viswanath, Kasisomayajula, Warren, Nicholas J.H., Warren, Graham W., Alberg, Anthony J.

Source: Journal of clinical oncology. 40(35):4144-4155

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100176794690.0x000001&indx=1&recIds=ETOCvdc_100176794690.0x000001

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

Authors: Herbst, Roy S., Majem, Margarita, Barlesi, Fabrice, Carcereny, Enric, Chu, Quincy, Monnet, Isabelle, Sanchez-Hernandez, Alfredo, Dakhil, Shaker, Camidge, D. Ross, Winzer, Leanne, Soo-Hoo, Yee, Cooper, Zachary A., Kumar, Rakesh, Bothos, John, Aggarwal, Charu, Martinez-Marti, Alex

Source: Journal of clinical oncology. 40(29):3383-3393

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172813254.0x000001&indx=1&recIds=ETOCvdc_100172813254.0x000001

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

Authors: Reckamp, Karen L., Redman, Mary W., Dragnev, Konstantin H., Minichiello, Katherine, Villaruz, Liza C., Faller, Bryan, Al Baghdadi, Tareq, Hines, Susan, Everhart, Leah, Highleyman, Louise, Papadimitrakopoulou, Vassiliki, Gandara, David R., Kelly, Karen, Herbst, Roy S.

Source: Journal of clinical oncology. 40(21):2295-2306

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100167477114.0x000001&indx=1&recIds=ETOCvdc_100167477114.0x000001

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Authors: Hirsch, Fred R., Redman, Mary W., Moon, James, Agustoni, Francesco, Herbst, Roy S., Semrad, Thomas J., Varella-Garcia, Marileila, Rivard, Chris J., Kelly, Karen, Gandara, David R., Mack, Philip C.

Source: Clinical lung cancer. 23(1):60-71

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100153309102.0x000001&indx=1&recIds=ETOCvdc_100153309102.0x000001

Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling

Authors: Moutafi, Myrto, Martinez-Morilla, Sandra, Divakar, Prajan, Vathiotis, Ioannis, Gavrielatou, Niki, Aung, Thazin Nwe, Yaghoobi, Vesal, Fernandez, Aileen I., Zugazagoitia, Jon, Herbst, Roy S., Schalper, Kurt A., Rimm, David L.

Source: In Journal of Thoracic Oncology August 2022 17(8):991-1001

Development of an immunohistochemical assay for Siglec-15

Authors: Shafi, Saba, Aung, Thazin Nwe, Robbins, Charles, Zugazagoitia, Jon, Vathiotis, Ioannis, Gavrielatou, Niki, Yaghoobi, Vesal, Fernandez, Aileen, Niu, Shuqiong, Liu, Linda N., Cusumano, Zachary T., Leelatian, Nalin, Cole, Kimberley, Wang, He, Homer, Robert, Herbst, Roy S., Langermann, Sol, Rimm, David L.

Source: In Laboratory Investigation July 2022 102(7):771-778

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Authors: Wu, Yi-Long, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W., Kim, Sang-We, Kato, Terufumi, Laktionov, Konstantin, Vu, Huu Vinh, Wang, Zhijie, Lu, Shun, Lee, Kye Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A., Zeng, Lingmin, Atasoy, Ajlan, Herbst, Roy S., Tsuboi, Masahiro

Source: In Journal of Thoracic Oncology March 2022 17(3):423-433

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Authors: Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., Herbst, Roy S.

Source: In Journal of Thoracic Oncology November 2021 16(11):1872-1882

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Authors: Herbst, Roy S., Garon, Edward B., Kim, Dong-Wan, Cho, Byoung Chul, Gervais, Radj, Perez-Gracia, Jose L., Han, Ji-Youn, Majem, Margarita, Forster, Martin D., Monnet, Isabelle, Novello, Silvia, Gubens, Matthew A., Boyer, Michael, Su, Wu-Chou, Samkari, Ayman, Jensen, Erin H., Kobie, Julie, Piperdi, Bilal, Baas, Paul

Source: In Journal of Thoracic Oncology October 2021 16(10):1718-1732

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Authors: Mansfield, Aaron S., Herbst, Roy S., de Castro, Gilberto, Jr., Hui, Rina, Peled, Nir, Kim, Dong-Wan, Novello, Silvia, Satouchi, Miyako, Wu, Yi-Long, Garon, Edward B., Reck, Martin, Robinson, Andrew G., Samkari, Ayman, Piperdi, Bilal, Ebiana, Victoria, Lin, Jianxin, Mok, Tony S.K.

Source: In JTO Clinical and Research Reports August 2021 2(8)

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Authors: Owonikoko, Taofeek K., Redman, Mary W., Byers, Lauren A., Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Al Baghdadi, Tareq, Lara, Primo, Jr., Miao, Jieling, Kelly, Karen, Ramalingam, Suresh S., Herbst, Roy S., Papadimitrakopoulou, Vassiliki, Gandara, David R.

Source: In Clinical Lung Cancer May 2021 22(3):187-194

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Authors: Borghaei, Hossein, Redman, Mary W., Kelly, Karen, Waqar, Saima N., Robert, Francisco, Kiefer, Gauri J., Stella, Philip J., Minichiello, Katherine, Gandara, David R., Herbst, Roy S., Papadimitrakopoulou, Vassiliki A.

Source: In Clinical Lung Cancer May 2021 22(3):178-186

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Authors: Waqar, Saiama N., Redman, Mary W., Arnold, Susanne M., Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Gandara, David R., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tanna, Saloni H., Raddin, Ryan S., Minichiello, Katherine, Bradley, Jeffrey D., Kelly, Karen, Herbst, Roy S., Papadimitrakopoulou, Vassiliki A.

Source: In Clinical Lung Cancer May 2021 22(3):170-177